[go: up one dir, main page]

WO2006044509A3 - Methods of treating vascular injuries - Google Patents

Methods of treating vascular injuries Download PDF

Info

Publication number
WO2006044509A3
WO2006044509A3 PCT/US2005/036770 US2005036770W WO2006044509A3 WO 2006044509 A3 WO2006044509 A3 WO 2006044509A3 US 2005036770 W US2005036770 W US 2005036770W WO 2006044509 A3 WO2006044509 A3 WO 2006044509A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypertension
methods
treating vascular
restenosis
vascular injuries
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/036770
Other languages
French (fr)
Other versions
WO2006044509A2 (en
Inventor
Leona E Ling
Kai Fu
Alan Gill
Philip J Gotwals
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Priority to CA002584248A priority Critical patent/CA2584248A1/en
Priority to EP05813747A priority patent/EP1804801A2/en
Priority to AU2005295734A priority patent/AU2005295734A1/en
Priority to JP2007536868A priority patent/JP2008516962A/en
Publication of WO2006044509A2 publication Critical patent/WO2006044509A2/en
Publication of WO2006044509A3 publication Critical patent/WO2006044509A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention relates to use of compounds and implantable devices including those compounds in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, lung and renal), and hypertension (e.g., primary and secondary hypertension, systolic hypertension, pulmonary hypertension, and hypertension-induced vascular remodeling resulting in target organ damage).
PCT/US2005/036770 2004-10-15 2005-10-13 Methods of treating vascular injuries Ceased WO2006044509A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002584248A CA2584248A1 (en) 2004-10-15 2005-10-13 Methods of treating vascular injuries
EP05813747A EP1804801A2 (en) 2004-10-15 2005-10-13 Methods of treating vascular injuries
AU2005295734A AU2005295734A1 (en) 2004-10-15 2005-10-13 Methods of treating vascular injuries
JP2007536868A JP2008516962A (en) 2004-10-15 2005-10-13 How to treat vascular injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61911604P 2004-10-15 2004-10-15
US60/619,116 2004-10-15

Publications (2)

Publication Number Publication Date
WO2006044509A2 WO2006044509A2 (en) 2006-04-27
WO2006044509A3 true WO2006044509A3 (en) 2006-08-17

Family

ID=36203501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/036770 Ceased WO2006044509A2 (en) 2004-10-15 2005-10-13 Methods of treating vascular injuries

Country Status (6)

Country Link
EP (1) EP1804801A2 (en)
JP (1) JP2008516962A (en)
AR (1) AR051587A1 (en)
AU (1) AU2005295734A1 (en)
CA (1) CA2584248A1 (en)
WO (1) WO2006044509A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427626B2 (en) 2003-05-16 2008-09-23 Astrazeneca Ab 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
US7446105B2 (en) 2002-03-09 2008-11-04 Astrazeneca Ab Pyrimidine compounds
US7465728B2 (en) 2002-03-09 2008-12-16 Astrazeneca Ab Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
US7485638B2 (en) 2002-03-09 2009-02-03 Astrazeneca Ab Pyrimidine compounds
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US8299066B2 (en) 2008-04-21 2012-10-30 Shionogi & Co., Ltd. Compounds having NPY Y5 receptor antagonistic activity
US8703760B2 (en) 2009-12-18 2014-04-22 Mitsubishi Tanabe Pharma Corporation Antiplatelet agent
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2008009077A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
PL2049502T3 (en) 2006-07-28 2012-06-29 Novartis Ag 2,4-substituted quinazolines as lipid kinase inhibitors
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
DK2497470T3 (en) 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
ES2393430T3 (en) * 2007-10-17 2012-12-21 Novartis Ag Imidazo [1,2-A] -pyridine derivatives useful as ALK inhibitors
KR20150065958A (en) * 2008-01-25 2015-06-15 이 아이 듀폰 디 네모아 앤드 캄파니 Fungicidal hetercyclic compounds
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2009271003A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
WO2010009155A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Fused heterocyclyc inhibitor compounds
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
WO2010080357A1 (en) * 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
CN102438993A (en) * 2009-05-19 2012-05-02 陶氏益农公司 Compounds and methods for controlling fungi
CA2763786C (en) 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
US20120220581A1 (en) 2009-10-30 2012-08-30 Janssen-Cilag, S.A. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
JP5959330B2 (en) * 2011-06-17 2016-08-02 田辺三菱製薬株式会社 New antiplatelet drugs
EP2723744B1 (en) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
KR20150020228A (en) 2012-05-31 2015-02-25 에프. 호프만-라 로슈 아게 Aminoquinazoline and pyridopyrimidine derivatives
RU2657540C2 (en) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4]triazolo[4,3-a]quinoxaline compounds and pde 10 inhibitors for use in treatment of neurological or metabolic disorders
ES2607184T3 (en) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Phosphodiesterase 10 enzyme inhibitors
CA2878435C (en) * 2012-07-26 2020-08-25 F. Hoffmann-La Roche Ag Benzisoxazole modulators of neurogenesis
TWI600654B (en) 2012-11-19 2017-10-01 艾姆公司 Compounds and compositions for the treatment of parasitic diseases
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
ES2759240T3 (en) * 2014-04-08 2020-05-08 Rigel Pharmaceuticals Inc 2,3-Disubstituted pyridine compounds as TGF-beta inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
WO2018124001A1 (en) * 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Bmp-signal-inhibiting compound
KR20240032157A (en) 2017-05-02 2024-03-08 노파르티스 아게 Combination therapy
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN113795490A (en) 2019-05-13 2021-12-14 诺华股份有限公司 Novel crystalline forms of N- (3- (2- (2-hydroxyethoxy) -6-morpholinopyridin-4-yl) -4-methylphenyl) -2 (trifluoromethyl) isonicotinamide as Raf inhibitors for the treatment of cancer
CN114105958B (en) * 2021-12-03 2022-11-22 郑州大学第一附属医院 Hydroximic acid-containing 2-phenylamino pyrimidine derivatives and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087304A2 (en) * 2002-04-04 2003-10-23 Biogen, Inc. Tri-substituted heteroaryls and methods of making and using the same
WO2004022054A1 (en) * 2002-09-06 2004-03-18 Biogen Idec Ma Inc. Pyrazolopyridines and methods of making and using the same
WO2004021989A2 (en) * 2002-09-06 2004-03-18 Biogen Idec Ma Inc. Imidazolopyridines and methods of making and using the same
WO2004026306A2 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004060362A2 (en) * 2003-01-02 2004-07-22 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-β
WO2004072033A2 (en) * 2003-02-12 2004-08-26 Biogen Idec Ma Inc. Pyrazoles and methods of making and using the same
WO2004078110A2 (en) * 2003-03-04 2004-09-16 Pfizer Products Inc. Fused imizadoles as transforming growth factor (tgf) inhibitors
WO2006026305A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc Pyrimidinylpyrazoles as tgf-beta inhibitors
WO2006026306A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as tgf-beta inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087304A2 (en) * 2002-04-04 2003-10-23 Biogen, Inc. Tri-substituted heteroaryls and methods of making and using the same
WO2004022054A1 (en) * 2002-09-06 2004-03-18 Biogen Idec Ma Inc. Pyrazolopyridines and methods of making and using the same
WO2004021989A2 (en) * 2002-09-06 2004-03-18 Biogen Idec Ma Inc. Imidazolopyridines and methods of making and using the same
WO2004026306A2 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004060362A2 (en) * 2003-01-02 2004-07-22 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-β
WO2004072033A2 (en) * 2003-02-12 2004-08-26 Biogen Idec Ma Inc. Pyrazoles and methods of making and using the same
WO2004078110A2 (en) * 2003-03-04 2004-09-16 Pfizer Products Inc. Fused imizadoles as transforming growth factor (tgf) inhibitors
WO2006026305A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc Pyrimidinylpyrazoles as tgf-beta inhibitors
WO2006026306A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as tgf-beta inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYAN SARAH T ET AL: "Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury.", JOURNAL OF VASCULAR RESEARCH, vol. 40, no. 1, 2003, pages 37 - 46, XP009066791, ISSN: 1018-1172 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
US7446105B2 (en) 2002-03-09 2008-11-04 Astrazeneca Ab Pyrimidine compounds
US7465728B2 (en) 2002-03-09 2008-12-16 Astrazeneca Ab Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
US7485638B2 (en) 2002-03-09 2009-02-03 Astrazeneca Ab Pyrimidine compounds
US7427626B2 (en) 2003-05-16 2008-09-23 Astrazeneca Ab 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
US8299066B2 (en) 2008-04-21 2012-10-30 Shionogi & Co., Ltd. Compounds having NPY Y5 receptor antagonistic activity
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US8415345B2 (en) 2008-05-06 2013-04-09 Glaxo SmithKline LLC Benzene sulfonamide thiazole and oxazole compounds
US8642759B2 (en) 2008-05-06 2014-02-04 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
US9233956B2 (en) 2008-05-06 2016-01-12 Novartis Ag Benzene sulfonamide thiazole and oxazole compounds
US8703760B2 (en) 2009-12-18 2014-04-22 Mitsubishi Tanabe Pharma Corporation Antiplatelet agent
US9533983B2 (en) 2009-12-18 2017-01-03 Mitsubishi Tanabe Pharma Corporation Antiplatelet agent
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK

Also Published As

Publication number Publication date
JP2008516962A (en) 2008-05-22
WO2006044509A2 (en) 2006-04-27
AU2005295734A1 (en) 2006-04-27
AR051587A1 (en) 2007-01-24
EP1804801A2 (en) 2007-07-11
CA2584248A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2006044509A3 (en) Methods of treating vascular injuries
EA200702358A1 (en) COMBINATION OF PDE4 INHIBITOR AND DERIVATIVE TETRAHYDROBIOPTERIN
UY28958A1 (en) NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA
EP1799154A4 (en) VASCULAR STENT AND METHOD OF MANUFACTURING THE STENT THERAPY
NO20054369L (en) Use of an IBAT inhibitor for the treatment and prophylaxis of constipation
ATE428372T1 (en) COATING OF STENTS TO PREVENT RESTENOSIS
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
ATE448206T1 (en) BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BONE DISEASES
WO2008005535A3 (en) Expandable vascular endoluminal prostheses
NO20034590D0 (en) Procedures for the treatment of vascular disease
NO2007010I1 (en) Sitagliptin, optionally in the form of a pharmaceutically acceptable salt
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
NO20043370L (en) N-pyrazinylphenylsulfonamides and their use in the treatment of chemokine-mediated diseases
NO20055941L (en) Use of a composition comprising a PDE4 inhibitor and a PDE5 inhibitor
EP1827478A4 (en) Methods of treatment for injured or diseased joints
ITMI20040876A1 (en) DEHACETYLASE-HDAC HISTONE INHIBITORS-WHICH HYPOLIPIDEMIZED AGENTS FOR THE THERAPY AND PREVENTION OF ARTERIOSCLEROSIS AND CARDIOVASCULAR DISEASES
EP1336619A3 (en) Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
MX2007005367A (en) Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure.
TW200628451A (en) Novel pyrimidine derivatives and their use
NO20033228L (en) Use of IL-18 inhibitors for the treatment and / or prevention of heart disease
IL178094A (en) Enantiomeric compounds, use thereof for the treatment or prevention of viral diseases, autoimmune diseases or organ or tissue transplantation rejection and methods of making same
NO20056218L (en) Substituted pyrrole derivatives and their use as HMF-CoA reductase inhibitors
WO2005058280A3 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2002080847A3 (en) Use of tumor necrosis factor inhibitors to treat cardiovascular disease
EA200702201A1 (en) ROFLUMILAST FOR TREATMENT OF PULMONARY HYPERTENSION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005295734

Country of ref document: AU

Ref document number: 554489

Country of ref document: NZ

Ref document number: 2007536868

Country of ref document: JP

Ref document number: 2584248

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005813747

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005813747

Country of ref document: EP